A Prospective Double-Blind Study of Retrovir in Early HIV Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002045|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients.
(12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.
|Condition or disease||Intervention/treatment|
|HIV Infections||Drug: Zidovudine|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Prospective Double-Blind Study of Retrovir in Early HIV Infection|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002045
|United States, North Carolina|
|Glaxo Wellcome Inc|
|Research Triangle Park, North Carolina, United States, 27709|